Sustainability Report for 2021
During 2021, we have taken important steps to create more value from our sustainability efforts by better articulating the health impact of our investment approach. As part of these efforts, we have also set out to fully integrate sustainability in our investment process and engagement with our portfolio companies. We hope you will enjoy reading more about our journey in Impilo’s Sustainability Report 2021.
Read the full report hereNews
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.